Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds GlaxoSmithKline's marketing prowess will be a major factor in the success of Lamictal, a drug developed for chemotherapy-induced neuropathic pain.

"Lamictal will likely incur only a modest shift away from Pfizer's Neurontin and other generic gabapentin for treating cancer pain, particularly in the United States," said Mary Fletcher-Louis, analyst at Decision Resources. "This phenomenon will depend crucially on GlaxoSmithKline's success in marketing this antiepileptic agent to medical oncologists. Medical oncologists administer the chemotherapy responsible for pain, and currently under-use gabapentin, a molecule that does not have a license for cancer pain."

The new Pharmacor study entitled Cancer Pain, also finds that undertreatment of cancer pain remains widespread, with inadequate clinician training, concern regarding side effects, tolerance and addiction, patient reluctance to complain, and structural barriers, all acting as obstacles to appropriate use of available strong narcotics.

About Neuropathic Cancer Pain

Neuropathic cancer pain is notoriously difficult to treat and occurs in approximately 30% of cancer pain patients, either as a result of tumor infiltration or neural structures or as a result of cytotoxic chemotherapy using platinum agents, vinca alkaloids, or taxanes. Complete resolution of pain with gabapentin is rare, and an urgent unmet need remains for an agent that is more effective than gabapentin in the treatment of neuropathic cancer pain.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,

Decision Resources, Inc. Acquires HealthLeaders, Inc.

View Now